Advertisement

Topics

Companies Related to "With debate around this SickleCell Disease Clinical Endpoints" [Most Relevant Company Matches] RSS

02:59 EST 15th December 2018 | BioPortfolio

Here are the most relevant search results for "With debate around this SickleCell Disease Clinical Endpoints" found in our extensive corporate database of over 50,000 company records.

Showing "With debate around this SickleCell Disease Clinical Endpoints" Companies 1–25 of 6,900+

Relevant

The Danish Council of Ethics

The Danish Council of Ethics' was established in 1988 to provide the Danish Parliament, official authorities and the public with ongoing advice and information about ethical problems raised by developments within the national health service and the field of biomedicine. This is accomplished by submitting reports and statements etc. in specified areas and by mounting debate generating activities in...


Valentis

Valentis is a biotechnology company that was engaged in the development of innovative products for peripheral arterial disease (PAD), a large and unsatisfied market. On July 11, 2006 Valentis announced that no statistically significant difference was seen in the primary endpoint or any of the secondary endpoints in its Phase IIb clinical trial of VLTS 934 in PAD. The primary efficacy endpoint in t...

Promisec, Inc.

Promisec (www.promisec.com) transforms how global companies manage and control their endpoints. Through actionable endpoint intelligence, Promisec makes managing complex IT operations simpler and more efficient for millions of endpoints. Promisec’s patented agentless technology provides full visibility of enterprise environments, often detecting previ...


BioCor LLC

Founded in 1998 and privately owned, BioCor is the only true Imaging CRO with extensive expertise in the design, execution and analysis of medical imaging-related clinical trials. BioCor’s capabilities enable us to integrate what previously were two independent areas of clinical development services, those services offered by traditional CROs, and those offered by imaging core laboratories...

CRDE Sp. j.

CRDE was founded in 2002 as niche CRO focused on managing clinical trials phase I-IV in oncology, metabolic disorders, cardiovascular disorders and pediatrics. Such therapeutic areas are very demanding and require specialized knowledge to understand study design and procedures, endpoints, safety issues and patient populationsOur Medical and Clinical Operations staff have proven experience and appl...

Neuraltus Pharmaceuticals

Neuraltus Pharmaceuticals, Inc. is a privately held biopharmaceutical company dedicated to developing and commercializing high-impact therapeutics that address critical unmet needs, primarily in the treatment of neurodegenerative diseases. Neuraltus has three clinical-stage programs in its development pipeline, including potential treatments for Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's...

Komodo Health

Komodo Health is a healthcare technology company focused on addressing the global burden of disease through the most representative and actionable healthcare map. Komodo Health’s real-time intelligence engine provides healthcare leaders with the tools to modernize and improve the way they engage and serve the medical community, resulting in a more tra...

BioTechNews Denmark

TopoTarget and CuraGen Announce Initiation of NCI-sponsored Phase II Clinical Trial with PXD101 for MesotheliomaTopoTarget A/S and CuraGen Corporation announced today the initiation of patient dosing in a Phase II clinical trial evaluating the activity of PXD101, a small molecule histone deacetylase (HDAC) inhibitor, for the treatment of mesothelioma. This trial is being sponsored by the National ...

Stratodesk

Stratodesk provides a one-for-all operating and management solution for virtual desktop infrastructure (VDI) endpoints. Organizations from small businesses to large enterprises and governments can achieve double-digit percentage cost reductions and dramatically improved security, while retaining existing hardware and being able to choose endpoint devices i...

NephroGenex, Inc.

NephroGenex (www.nephrogenex.com) is a drug development company focusing on kidney disease. More than 20 million Americans have some form of chronic kidney disease, and over 400,000 in the US have end stage renal disease requiring dialysis, making renal disease one of the costliest illnesses to treat. The Company is developing Pyridorin(TM) (pyridoxamine dihydrochloride) as a treatment to slow t...

The Pew Initiative on Food and Biotechnology

Mission StatementAs often occurs with the introduction of transformative technologies, the development of genetically modified foods and other products of agricultural biotechnology has generated significant public debate.The Pew Initiative on Food and Biotechnology was established in 2001 to be an independent and objective source of credible information on agricultural biotechnology for the publi...

Axonyx

Axonyx is a biopharmaceutical company focused on the acquisition and development of proprietary products and technologies for the treatment and diagnosis of Alzheimer's Disease and other memory-related cognitive disorders including prion diseases such as Mad Cow Disease. After completion of a Phase II Proof of Concept clinical study in October of 2001 for Phenserine, Axonyx's lead product for Alzh...

Probably Relevant

EPIX Pharmaceuticals

EPIX Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products through the use of proprietary technology to better diagnose, treat and manage patients. The company has five internally-discovered therapeutic and imaging drug candidates currently in clinical trials targeting conditions such as depression, Alzheimer's disease, ...

BMJ Publishing Group

To be the world's most influential and widely read medical journal.Mission To lead the debate on health, and to engage, inform, and stimulate doctors, researchers and other health professionals in ways that will improve outcomes for patients.

United Neuroscience, Inc.

United Neuroscience (UNS) is a clinical-stage biotech company dedicated to the development of first-in-class, disease-modifying therapeutics for Alzheimer’s disease and other neurodegenerative disorders. UNS was founded to address the social and economic burden of neurodegenerative proteinopathies and seeks to rapidly advance candidates into and through ...

Vince & Associates Clinical Research

Since its formation in 2001 Vince & Associates Clinical Research has grown to become one of the leading multi-specialty clinical research sites in the US offering Phase I-IV clinical trials. Dr. Vince and his team are well known for their recruitment and retention of research volunteers in clinical trials including disease state populations as well as heal...

Diagnostic Potentials Ltd

Diagnostic Potentials Ltd is developing a range of diagnostic and monitoring systems for Central Nervous system (CNS) disease states. The first product that has been developed is a system for the early diagnosis of Alzheimer's Disease that will enable clinical consultants to make a positive decision on the care of the patient and on the prescribing of drugs.CNS disorders, such as Alzheimer's, Park...

Aerpio Therapeutics

Aerpio Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on advancing innovative therapies for the treatment of diabetic eye disease and inflammatory bowel disease. Aerpio is a leader in the development of small molecule drugs based on Tie-2 activation and the stabilization of Hypoxia-inducible Factor 1α (HIF-1α). The company’s ...

THE FOUNDATION FOR INNOVATION IN MEDICINE

FIM, The Foundation for Innovation in Medicine, was established in 1976 by Stephen L. DeFelice, M.D. It is a nonprofit foundation whose purpose is to accelerate medical discovery by creating a more productive clinical research community. The cost and risk to conduct clinical research, the critical step in medical discovery, are major factors that retard the availability of new therapies that can e...

SCAI

Headquartered in Washington, D.C., the Society for Cardiovascular Angiography and Interventions is a 4,000-member professional organization representing invasive and interventional cardiologists in approximately 70 nations. SCAI's mission is to promote excellence in invasive and interventional cardiovascular medicine through physician education and representation, and advancement of quality standa...

Trophos SA

Trophos is a biopharmaceutical company committed to the discovery and development of novel therapeutic compounds to treat neurodegenerative diseases.Trophos has a fully integrated pre-clinical and clinical capability. Our discovery strategy is based on screening chemical collections of small molecules on models of sick neurons, using the class of neurons affected in each type of disease. Since com...

Aerpio Therapeutics, Inc.

Aerpio Therapeutics, Inc. is a clinical‐stage biopharmaceutical company focused on advancing innovative therapies for the treatment of diabetic eye disease and inflammatory bowel disease. Aerpio is a leader in the development of small molecule drugs based on Tie2 activation and the stabilization of Hypoxia-inducible Factor 1α (HIF‐1α). The Company...

TD2

Translational Drug Development (TD2) is an oncology development organization that provides innovative services for oncology-focused biopharmaceutical companies. Using a dedicated team of professionals with broad experience and understanding in drug development, TD2 is uniquely positioned to support improved and accelerated development of medicines for life...

KBP Biosciences

KBP Biosciences is a clinical-stage biotechnology company dedicated to the research and development of innovative medicines that treat unmet medical needs of patients throughout the world. Based on cutting edge new drug development ideas and its own medicinal chemistry and CMC strengths, together with internal/external clinical development and regulatory e...

Biopharm conference

Around the globe, healthcare is at or near the top of every policy and economic agenda. Cost, access and innovation dominate the public debate. This increased attention has focused a new degree of scrutiny on business practices in the life sciences and pharmaceutical industries and will impact everything from how the industry accesses capital, to deal terms, to the nature of innovation itself


More From BioPortfolio on "With debate around this SickleCell Disease Clinical Endpoints"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks